Want to see AU:PIQ full AI Analyst Report?
PIQ Stock Chart & Stats
AU$0.67
AU$0.03(4.23%)
At close: 4:00 PM EST
AU$0.67
AU$0.03(4.23%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.86
Previous CloseN/A
Volume90.30K
Average Volume (3M)426.90K
Market Cap
AU$25.63M
Enterprise ValueAU$14.49M
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$681.45K
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding165,373,120
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$5.90M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsHaving both diagnostics (commercial tests) and fee-for-service proteomics provides durable revenue optionality. Services can generate repeat project cash while diagnostics scale with clinical adoption or licensing, reducing single-stream concentration risk over the next 2–6 months.
Proprietary Diagnostic AssetOwning a clinically oriented blood test for diabetic kidney disease represents a structural competitive asset: proprietary biomarkers and clinical differentiation can support durable market positioning, licensing, and clinical adoption pathways that persist beyond short-term cycles.
Low Financial LeverageMinimal debt provides financial flexibility and lowers solvency risk, giving management runway to fund R&D, commercialization or absorb revenue volatility without immediate refinancing pressure—an important structural buffer over the coming months.
Bears Say
Steep Revenue DeclineA >70% year decline in revenue is a durable headwind: it erodes scale economics, weakens bargaining power with partners, and reduces resources for commercialization and trials. Unless reversed via new contracts or adoption, top-line contraction limits strategic options.
Persistent Negative ProfitabilitySustained negative operating and net margins indicate structural cost or revenue model issues. Ongoing unprofitability depletes equity, complicates partner negotiations and makes self-funding growth difficult without material margin recovery or cost restructuring.
Negative Operating And Free Cash FlowConsistent negative OCF and FCF mean the business is burning cash to operate. That forces reliance on external funding or dilution to sustain R&D and commercial activities, creating a structural constraint on execution and long-term independence.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.10 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$25.63M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 40 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.04.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,373,120 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PIQ Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.94%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Technical Analysis
Telix Pharmaceuticals
―
Vectus Biosystems Limited
―
AnteoTech Ltd
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―